Drugs / HuCNS-SC
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01238315 | Nov 2010 → Apr 2011 | neuronal ceroid lipofuscinosis | StemCells, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01005004 | Nov 2009 → Oct 2012 | Pelizaeus-Merzbacher disease, connatal form | StemCells, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01321333 | Mar 2011 → Apr 2015 | spinal cord injury | StemCells, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02467634 | Jun 2015 → May 2016 | age-related macular degeneration | StemCells, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02163876 | Oct 2014 → May 2016 | spinal cord injury | StemCells, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HuCNS-SC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02163876 ↗ |
| Modality | Cell therapy | “human central nervous system stem cells (HuCNS-SC®) transplantation” NCT01005004 ↗ |
| Route | Other | “intracerebral transplantation” NCT01005004 ↗ |